Biotechnology and biopharmaceutical industries will fuel future growth of the South Korean economy and it is time to focus more on human genome and DNA to ride on the advent of the boom in bio industries, the country’s largest conglomerate Samsung Group’s biopharmaceutical unit CEO said.
“Human genome and DNA have now become keywords and will lead a new industrial revolution,” said Samsung BioLogics Co. Chief Executive Kim Tae-han said on Wednesday during his lecture to Kyungpook National University students.
